

Ryuichi Harada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1695623/publications.pdf>

Version: 2024-02-01

44
papers

2,910
citations

236925

25
h-index

330143

37
g-index

48
all docs

48
docs citations

48
times ranked

2332
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Chirality of [18F]SMBT-1 in Imaging of Monoamine Oxidase-B. ACS Chemical Neuroscience, 2022, 13, 322-329.	3.5	6
2	Imaging of Reactive Astroglia by Positron Emission Tomography. Frontiers in Neuroscience, 2022, 16, 807435.	2.8	25
3	PET Imaging of Amyloid and Tau in Alzheimer's Disease. , 2022, , 307-323.		2
4	¹⁸ F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging. Journal of Nuclear Medicine, 2021, 62, 253-258.	5.0	57
5	Synthesis and evaluation of 2-pyrrolopyridinylquinoline derivatives as selective tau PET tracers for the diagnosis of Alzheimer's disease. Nuclear Medicine and Biology, 2021, 93, 11-18.	0.6	7
6	Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody. Scientific Reports, 2021, 11, 2588.	3.3	6
7	¹⁸ F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies. Frontiers in Aging Neuroscience, 2021, 13, 761010.	3.4	16
8	A concentration-based microscale method for ¹⁸ F-nucleophilic substitutions and its testing on the one-pot radiosynthesis of [18F]FET and [18F]fallypride. Applied Radiation and Isotopes, 2020, 166, 109361.	1.5	6
9	Site-Specific Labeling of F-18 Proteins Using a Supplemented Cell-Free Protein Synthesis System and O-2-[18F]Fluoroethyl-L-Tyrosine: [18F]FET-HER2 Affibody Molecule. Molecular Imaging and Biology, 2019, 21, 529-537.	2.6	13
10	Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site. Annals of Nuclear Medicine, 2019, 33, 375-382.	2.2	16
11	Correlations of ¹⁸ F-THK5351 PET with Postmortem Burden of Tau and Astroglia in Alzheimer Disease. Journal of Nuclear Medicine, 2018, 59, 671-674.	5.0	135
12	¹⁸ F-THK5351: TO TAU OR TO MAO-B? MOST OF THE [¹⁸ F]-THK5351 SIGNAL IS BLOCKED BY SELEGILINE. Alzheimer's and Dementia, 2018, 14, P181.	0.8	0
13	Involvement of the Precuneus/Posterior Cingulate Cortex Is Significant for the Development of Alzheimer's Disease: A PET (THK5351, PiB) and Resting fMRI Study. Frontiers in Aging Neuroscience, 2018, 10, 304.	3.4	72
14	Imaging Protein Misfolding in the Brain Using β -Sheet Ligands. Frontiers in Neuroscience, 2018, 12, 585.	2.8	30
15	Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathologica Communications, 2018, 6, 53.	5.2	54
16	The development and validation of tau PET tracers: current status and future directions. Clinical and Translational Imaging, 2018, 6, 305-316.	2.1	135
17	Monoamine oxidase B inhibitor, selegiline, reduces ¹⁸ F-THK5351 uptake in the human brain. Alzheimer's Research and Therapy, 2017, 9, 25.	6.2	285
18	[¹⁸ F]-THK5351: SUCCESSFUL REDUCTION OF OFF-TARGET BINDING OF QUINOLINE DERIVATIVES AS TAU-SELECTIVE PET TRACERS. Alzheimer's and Dementia, 2017, 13, P136.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Tau PET in Neurodegenerative Diseases Manifesting Dementia. , 2017, , 199-210.		0
20	Characteristics of Tau and Its Ligands in PET Imaging. Biomolecules, 2016, 6, 7.	4.0	86
21	Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimerâ€™s Disease Patients Measured Using [18F] THK-5351. PLoS ONE, 2016, 11, e0158460.	2.5	85
22	P4â€²70: Identification of Wavelengthâ€²Dependent Compounds for Imaging LEWY Pathology. Alzheimer's and Dementia, 2016, 12, P1136.	0.8	0
23	In vivo visualization of tau deposits in corticobasal syndrome by ¹⁸ F-THK5351 PET. Neurology, 2016, 87, 2309-2316.	1.1	105
24	Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2211-2218.	6.4	18
25	Advances in the development of tau PET radiotracers and their clinical applications. Ageing Research Reviews, 2016, 30, 107-113.	10.9	57
26	Synthesis and Characterization of ¹⁸ F-Interleukin-8 Using a Cell-Free Translation System and 4- ¹⁸ F-Fluoro-l-Proline. Journal of Nuclear Medicine, 2016, 57, 634-639.	5.0	8
27	¹⁸ F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. Journal of Nuclear Medicine, 2016, 57, 208-214.	5.0	282
28	Structureâ€²Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease. Journal of Nuclear Medicine, 2016, 57, 608-614.	5.0	56
29	Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer. Molecular Imaging and Biology, 2016, 18, 258-266.	2.6	29
30	IC-P-167: Validation of the binding specificity of Tau PET tracer [18 F]THK-5351 on postmortem human brain samples. , 2015, 11, P111-P111.		0
31	Longitudinal Assessment of Tau Pathology in Patients with Alzheimerâ€™s Disease Using [18F]THK-5117 Positron Emission Tomography. PLoS ONE, 2015, 10, e0140311.	2.5	75
32	O4-02-04: Validation of the binding specificity of Tau PET tracer [18 F]THK-5351 on postmortem human brain samples. , 2015, 11, P271-P271.		3
33	[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1052-1061.	6.4	117
34	Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 18-24.	1.0	31
35	Tau PET Imaging in Alzheimerâ€™s Disease. Current Neurology and Neuroscience Reports, 2014, 14, 500.	4.2	141
36	Use of a Benzimidazole Derivative BF-188 in Fluorescence Multispectral Imaging for Selective Visualization of Tau Protein Fibrils in the Alzheimerâ€™s Disease Brain. Molecular Imaging and Biology, 2014, 16, 19-27.	2.6	42

#	ARTICLE	IF	CITATIONS
37	Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. <i>Brain</i> , 2014, 137, 1762-1771.	7.6	234
38	In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 816-826.	6.4	156
39	Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 11.	6.2	68
40	P1-010: BINDING CHARACTERIZATION OF TAU PET TRACER 18F-THK5117 IN NON-ALZHEIMER'S NEURODEGENERATIVE DISEASES. , 2014, 10, P307-P308.		1
41	Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 125-132.	6.4	100
42	Novel ¹⁸ F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1420-1427.	5.0	259
43	Synthesis of [11C]interleukin 8 using a cell-free translation system and l-[11C]methionine. <i>Nuclear Medicine and Biology</i> , 2012, 39, 155-160.	0.6	8
44	The challenges of tau imaging. <i>Future Neurology</i> , 2012, 7, 409-421.	0.5	82